The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Jul 5

PMID 35785334

Authors

Aleksandrs Krigers

Daniel Pinggera

Matthias Demetz

Lisa-Marie Kornberger

Johannes Kerschbaumer

Claudius Thome

Christian F Freyschlag

Affiliations

Soon will be listed here.

Abstract

Introduction: Tumor-treating fields (TTFs) are a specific local oncological treatment modality in glioblastoma multiforme WHO° IV (GBM). Their mechanism of action is based on the effect of electrical fields interfering with the mitotic activity of malignant cells. Prospective studies have demonstrated efficacy, but TTF benefits are still controversially discussed. This treatment was implemented in our center as the standard of care in January 2016. We thus discuss the current state of the art and our long-term experience in the routine application of TTF.

Methods: The data of 48 patients suffering from GBM and treated with TTF were assessed and compared with previously published studies. Up-to-date information from open sources was evaluated.

Results: A total of 31 males and 17 females harboring a GBM were treated with TTF, between January 2016 and August 2021, in our center. In 98% of cases, TTFs were started within 6 weeks after concomitant radiochemotherapy (Stupp protocol). Mean overall survival was 22.6 months (95% CI: 17.3-27.9). Current indications, benefits, and restrictions were evaluated. Future TTF opportunities and ongoing studies were reviewed.

Conclusion: TTFs are a feasible and routinely applicable specific oncological treatment option for glioblastoma multiforme WHO° IV. Further research is ongoing to extend the indications and the efficacy of TTF.

Citing Articles

Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study.

Woo P, Pu J, Li L, Wong D, Hui V, Chan D J Neurooncol. 2025; .

PMID: 40067514 DOI: 10.1007/s11060-025-04985-3.

Real-world experience with TTFields in glioma patients with emphasis on therapy usage.

Jelgersma C, Alsolivany J, Akkas G, Wasilewski D, Gastl B, Misch M Front Oncol. 2025; 14():1430793.

PMID: 39839796 PMC: 11747310. DOI: 10.3389/fonc.2024.1430793.

Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.

Sharifian A, Kazemian A, Farzin M, Amirkhani N, Farazmand B, Naderi S Neurooncol Adv. 2024; 6(1):vdae195.

PMID: 39664679 PMC: 11632829. DOI: 10.1093/noajnl/vdae195.

The neglected burden of chronic hypoxia on the resistance of glioblastoma multiforme to first-line therapies.

Bou-Gharios J, Noel G, Burckel H BMC Biol. 2024; 22(1):278.

PMID: 39609830 PMC: 11603919. DOI: 10.1186/s12915-024-02075-w.

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

Khagi S, Kotecha R, Gatson N, Jeyapalan S, Abdullah H, Avgeropoulos N Oncologist. 2024; 30(2).

PMID: 39401002 PMC: 11883162. DOI: 10.1093/oncolo/oyae227.

References

Shi W, Blumenthal D, Oberheim Bush N, Kebir S, Lukas R, Muragaki Y . Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. J Neurooncol. 2020; 148(3):489-500. PMC: 7438370. DOI: 10.1007/s11060-020-03540-6. View

McClelland 3rd S, Henrikson C, Ciporen J, Jaboin J, Mitin T . Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case. World Neurosurg. 2018; 119:58-60. DOI: 10.1016/j.wneu.2018.07.162. View

Carrieri F, Smack C, Siddiqui I, Kleinberg L, Tran P . Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment. Front Oncol. 2020; 10:575992. PMC: 7664989. DOI: 10.3389/fonc.2020.575992. View

Mun E, Babiker H, Weinberg U, Kirson E, Von Hoff D . Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2017; 24(2):266-275. DOI: 10.1158/1078-0432.CCR-17-1117. View

Weller M, van den Bent M, Hopkins K, Tonn J, Stupp R, Falini A . EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014; 15(9):e395-403. DOI: 10.1016/S1470-2045(14)70011-7. View

Green A, Mulcahy Levy J, Vibhakar R, Hemenway M, Madden J, Foreman N . Tumor treating fields in pediatric high-grade glioma. Childs Nerv Syst. 2017; 33(7):1043-1045. DOI: 10.1007/s00381-017-3431-0. View

Connock M, Auguste P, Dussart C, Guyotat J, Armoiry X . Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. J Neurooncol. 2019; 143(3):605-611. DOI: 10.1007/s11060-019-03197-w. View

Omar A . Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. J Vis Exp. 2014; (92):e51638. PMC: 4541554. DOI: 10.3791/51638. View

Toms S, Kim C, Nicholas G, Ram Z . Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2018; 141(2):467-473. PMC: 6342854. DOI: 10.1007/s11060-018-03057-z. View

10.

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X . The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016; 18(8):1129-36. PMC: 4933490. DOI: 10.1093/neuonc/now102. View

11.

Onken J, Staub-Bartelt F, Vajkoczy P, Misch M . Acceptance and compliance of TTFields treatment among high grade glioma patients. J Neurooncol. 2018; 139(1):177-184. DOI: 10.1007/s11060-018-2858-9. View

12.

Gera N, Yang A, Holtzman T, Lee S, Wong E, Swanson K . Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015; 10(5):e0125269. PMC: 4444126. DOI: 10.1371/journal.pone.0125269. View

13.

Penas-Prado M . Practice-Changing Abstracts From the 2016 Society for Neuro-Oncology Annual Scientific Meeting. Am Soc Clin Oncol Educ Book. 2017; 37:187-191. DOI: 10.1200/EDBK_175563. View

14.

Linder B, Schiesl A, Voss M, Rodel F, Hehlgans S, Gullulu O . Dexamethasone Treatment Limits Efficacy of Radiation, but Does Not Interfere With Glioma Cell Death Induced by Tumor Treating Fields. Front Oncol. 2021; 11:715031. PMC: 8361446. DOI: 10.3389/fonc.2021.715031. View

15.

Lee W, Seo S, Chung H, Park J, Kim J, Kim E . Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy. Am J Cancer Res. 2021; 11(9):4582-4594. PMC: 8493382. View

16.

Crawford J, Saria M, Dhall G, Margol A, Kesari S . Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series. Cureus. 2020; 12(10):e10804. PMC: 7641478. DOI: 10.7759/cureus.10804. View

17.

Hong P, Kudulaiti N, Wu S, Nie J, Zhuang D . Tumor treating fields: a comprehensive overview of the underlying molecular mechanism. Expert Rev Mol Diagn. 2021; 22(1):19-28. DOI: 10.1080/14737159.2022.2017283. View

18.

Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman R . Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020; 69(7):1191-1204. PMC: 7303058. DOI: 10.1007/s00262-020-02534-7. View

19.

Giladi M, Munster M, Schneiderman R, Voloshin T, Porat Y, Blat R . Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017; 12(1):206. PMC: 5747183. DOI: 10.1186/s13014-017-0941-6. View

20.

Poon M, Sudlow C, Figueroa J, Brennan P . Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020; 10(1):11622. PMC: 7363854. DOI: 10.1038/s41598-020-68011-4. View